AGENUS INC
For the period ended Dec 31, 2025. Filed Mar 16, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 16, 2026
AGEN$7.150.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(Amounts in thousands, except share and per share amounts)
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| ASSETS | ||
| Cash and cash equivalents | $2,998 | $40,437 |
| Accounts receivable | 1,831 | 407 |
| Related party note receivable from MiNK Therapeutics, Inc. | 5,179 | — |
| Prepaid expenses | 785 | 2,315 |
| Assets held for sale | 121,554 | — |
| Other current assets | 1,089 | 2,415 |
| Total current assets | 133,436 | 45,574 |
| Property, plant and equipment, net of accumulated amortization and depreciation of $47,468 and $72,553 at December 31, 2025 and 2024, respectively | 15,470 | 120,087 |
| Operating lease right-of-use assets | 7,744 | 27,308 |
| Goodwill | 24,092 | 24,092 |
| Acquired intangible assets, net of accumulated amortization of $17,325 and $16,986 at December 31, 2025 and 2024, respectively | 3,037 | 3,376 |
| Equity method investment in MiNK Therapeutics, Inc. | 24,277 | — |
| Due from related parties (MiNK Therapeutics, Inc.) | 15,435 | — |
| Other long-term assets | 3,307 | 5,834 |
| Total assets | $226,798 | $226,271 |
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT | ||
| Current portion, long-term debt | $44,655 | $2,698 |
| Current portion, liability related to sale of future royalties and milestones | 109,323 | 111,978 |
| Current portion, deferred revenue | - | 31 |
| Current portion, operating lease liabilities | 1,034 | 2,446 |
| Accounts payable | 82,987 | 61,470 |
| Accrued liabilities | 34,223 | 34,961 |
| Liabilities held for sale | 50,738 | |
| Other current liabilities | 529 | 7,817 |
| Total current liabilities | 323,489 | 221,401 |
| Long-term debt, net of current portion | - | 30,473 |
| Liability related to sale of future royalties and milestones, net of current portion | 169,660 | 224,389 |
| Deferred revenue, net of current portion | 1,143 | 1,143 |
| Operating lease liabilities, net of current portion | 10,108 | 54,551 |
| Other long-term liabilities | 259 | 738 |
| Commitments and contingencies (Note 20) | ||
| STOCKHOLDERS’ DEFICIT | ||
| Preferred stock, par value $0.01 per share; 5,000,000 shares authorized: | ||
| Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at December 31, 2025 and 2024; liquidation value of $34,317 and $34,101 at December 31, 2025, and 2024, respectively | - | - |
| Common stock, par value $0.01 per share; 800,000,000 shares authorized at December 31, 2025 and 2024; 35,320,397 shares and 23,634,670 shares issued and outstanding at December 31, 2025 and 2024, respectively | 353 | 236 |
| Additional paid-in capital | 1,911,740 | 1,857,662 |
| Accumulated other comprehensive loss | (439) | (1,398) |
| Accumulated deficit | (2,182,765) | (2,182,880) |
| Total stockholders’ deficit attributable to Agenus Inc. | (271,111) | (326,380) |
| Non-controlling interest | (6,750) | 19,956 |
| Total stockholders’ deficit | (277,861) | (306,424) |
| Total liabilities, convertible preferred stock and stockholders’ deficit | $226,798 | $226,271 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.